Clinical trials: IgAN
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
- Conditions
- Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
- Trial name
- RENEW (NCT05162066)
- Testing
- BCX9930
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 2 people
- Sponsor
- BioCryst Pharmaceuticals
IgA Nephropathy
Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.
- Trial name
- NCT00885547
- Testing
- tripterygium wilfordii (TW)
- Volunteers
- 90 people
- Sponsor
- Nanjing University School of Medicine
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446459
- Testing
- mycophenolate mofetil (CellCept)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
IgA Nephropathy
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment …
- Trial name
- NCT04858724
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Ruijin Hospital
Bortezomib, Glomerulonephritis
Bortezomib for Treating Glomerular Diseases
Bortezomib is a proteasome inhibitor that inhibits autoantibody production, and reduces podocyte damage and mesangial hyperplasia caused by NF-κB activation in the kidney.
- Conditions
- Bortezomib, Glomerulonephritis, MN, MPGN
- Trial name
- NCT05383547
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
IgA Nephropathy
Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Trial name
- NCT07054684
- Testing
- BHV-1400
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biohaven Therapeutics Ltd.
Primary IgA Nephropathy
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
The goal of this clinical trial is to evaluate if obinutuzumab beta works to treat primary IgA nephropathy with active proliferative lesions in adults. It will also learn about the safety of obinutuzumab beta.
- Trial name
- NCT07888335
- Testing
- Obinutuzumab Beta
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
IgA Patients, Hydroxychloroquine
A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy
The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB.
- Trial name
- NCT02942381
- Testing
- Hydroxychloroquine Sulfate
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
IgA Nephropathy
Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN Investigation of differences between the treatments…
- Trial name
- STOP-IgAN (NCT00554502)
- Testing
- supportive therapy with: ACE-inhibitor / ARB / Statin, supportive and immunosuppressive therapy
- Where
- 34 sites in Germany
- Volunteers
- 148 people
- Sponsor
- RWTH Aachen University
Cancer
Wormwood in Chronic Progressive Disorders With Reduced Appetite
Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer.
- Trial name
- NCT01126931
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital Freiburg
Immunoglobulin A Nephropathy
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being…
- Trial name
- SPARTACUS (NCT05856760)
- Testing
- Sparsentan
- Where
- 30 sites in United States, Hong Kong
- Volunteers
- 48 people
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy (IgAN), Berger Disease
Monthly Dosing of Atacicept in IgAN
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
- Trial name
- NCT07020923
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Vera Therapeutics, Inc.
IgA Nephropathy (IgAN)
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
- Trial name
- NCT06670352
- Testing
- HSK39297 50mgBID, HSK39297 100mgBID, HSK39297 200mgQD
- Where
- 2 sites in China
- Volunteers
- 87 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
IgA Nephropathy
A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy
This is a survey of factors which affect a pathologically defined early or delayed diagnosis of IgA nephropathy in Guangdong General Hospital, Guangzhou, China.
- Trial name
- NCT01538433
- Where
- China
- Volunteers
- 603 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA…
- Trial name
- NCT04905212
- Testing
- Telitacicept 160mg, Telitacicept 240mg
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- RemeGen Co., Ltd.
IgA Nephropathy
Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Mycophenolate Mofetil in combination with corticosteroid in patients with advanced IgA nephropathy.
- Trial name
- AIGA (NCT02981212)
- Testing
- Mycophenolate Mofetil, ACE inhibitor, Corticosteroid
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Immunoglobulin A Nephropathy
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
- Trial name
- NCT05248659
- Testing
- Sibeprenlimab 400 mg s.c. Q4weeks
- Where
- 158 sites in United States, Argentina and 29 more
- Volunteers
- 600 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Glomerulonephritis, IGA Nephropathy
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy have been proved,and the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy.
- Trial name
- NCT00426348
- Testing
- Valsartan, Probucol
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangdong Provincial People's Hospital
Primary IgA Nephropathy
Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN
This replication of the NefIgArd trial of TRF-budesonide aims to use real-world data to evaluate the efficiency and safety of TRF-budesonide in the treatment of IgA nephropathy, from completing real-world research to providing…
- Trial name
- NCT06589752
- Testing
- TARPEYO 4 MG Delayed Release Oral Capsule, RAS inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital